公司資料
Eli Lilly 股價、新聞與催化劑
- 股票代碼:
- LLY
- 交易所:
- NYSE
- 產業:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- 所在地:
- United States
股票表現
1,149.85 USD (-0.62%)
收盤價
最後更新: 2026年10月1日
949B USD
市值
股價為何變動
截至 2026年10月1日，LLY 下跌 0.62%，收於 $1149.85。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Global Research-Based Medicines Company
Eli Lilly is a global pharmaceutical company that develops and commercializes medicines using capabilities in biotechnology, medicinal chemistry, and genetic medicine. Its research and commercial portfolio is concentrated in diabetes and obesity, neuroscience, immunology, and oncology, with external acquisitions increasingly adding genetic medicine, infectious disease, and neuropsychiatry programs.
Diabetes and Obesity Leadership
Lilly's largest franchise is built around incretin medicines for metabolic disease. Mounjaro is marketed for type 2 diabetes and Zepbound for chronic weight management and related complications, while oral GLP-1 candidate orforglipron, branded Foundayo in advance of potential commercialization, is intended to broaden access to incretin therapy without injection or food-and-water dosing restrictions. Retatrutide, a once-weekly GIP, GLP-1, and glucagon receptor agonist, is being developed for obesity and complications including obstructive sleep apnea and knee osteoarthritis pain.
Neuroscience and Immunology
The neuroscience portfolio includes Kisunla for early symptomatic Alzheimer's disease and acquired programs addressing sleep-wake disorders and treatment-resistant depression. In immunology, Lilly markets Ebglyss for atopic dermatitis and Omvoh for inflammatory bowel disease, supported by research across chronic inflammatory and autoimmune conditions.
Oncology Portfolio
Lilly's oncology business combines targeted small molecules, biologics, and biomarker-driven development. Commercial products include Jaypirca for B-cell malignancies, Retevmo for RET-driven cancers, and Inluriyo for estrogen receptor-positive breast cancer, while the pipeline includes olomorasib in KRAS G12C-mutated tumors and additional programs added through the acquisition of Ajax Therapeutics.
Genetic Medicine and External Innovation
The company is expanding beyond its traditional discovery platforms through acquisitions and partnerships. Orna Therapeutics and Kelonia Therapeutics add circular RNA and in vivo genetic medicine capabilities, Centessa adds sleep-wake assets, and additional transactions are establishing infectious disease and neuropsychiatry portfolios. VERVE-102, an in vivo PCSK9 base-editing program, illustrates Lilly's interest in potentially one-time genetic treatments for common cardiometabolic disease.
未來催化劑
- U.S. FDA submission of a Biologics License Application for retatrutide in obesity in the first quarter of 2027, supported by the completed Phase 3 registration package covering obesity, obstructive sleep apnea, and knee osteoarthritis pain.
- FDA review and potential decision on the submitted U.S. application for orforglipron in type 2 diabetes.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。